Abstrakt
Myeloma patients treated with anti-BCMA bispecific antibodies (bsAb) are at high risk of developing infections due to subsequent depletion of immunoglobulins (IG) and T cell exhaustion. Preventive measures include IG replacement, but no firm recommendations about timing and target levels exist.
We aimed to describe early infection incidence, severity, and IgG levels in patients treated with anti-BCMA bsAb.